Delivery of whole proteins is the next great challenge for medicine, as they can provide a therapeutic remedy without the side effects of traditional synthetic drug compounds. However, proteins are fragile and short lived in vivo and require a nano scale delivery vehicle to enable their circulation within the blood stream and delivery into the desired target cells.

MediVas has pioneered the development of a synthetic polymeric platform for the capture and stabilization of recombinant proteins into biocompatible particles for the administration of biologic therapeutics.  MediVas' technology employs polymer-bound cations to specifically capture the recombinant protein.  A significant advantage of this system is its simplicity: the same polymer platform can be used to capture almost any recombinant protein.  This technology has allowed the production of a wide variety of stable, protein-based prototype products, from antigen-based vaccines to antibody coated nanoparticles targeted for specific cell surface receptors to extended duration macromolecules such as Blood Factor IX and basal insulin. 

Please contact us to learn more about the many exciting opportunities in this area.